America’s Generic Drug Gamble: The Home‑Made Plan Still Needs a Prescription
In a plot twist that would make a pharmaceutical sitcom, the U.S. government announced it would produce generic drugs in its own soil, only to discover that the soil is a little too dry.
Trump Flirts with Kim, Casts Spy Shadows on Alice Huang While Praising Jensen’s ‘Lesson’
President Trump hints at a rendezvous with North Korea’s leader, questions the allegianc…
The plan, which promised to cut costs and boost domestic jobs, ran into the same stumbling block that makes any DIY project fail: a lack of cheap labor. While the Trump administration can’t resist the patriotic appeal of “Made in America” labels, the cost of hiring a skilled chemist in Washington, D.C. is more expensive than a latte from a local café.
India’s supply chain, meanwhile, has become a well‑tuned orchestra of low‑price raw materials, efficient logistics, and a workforce that can handle 1,000s of pills per day. The U.S. would have to build a similar symphony from scratch, which, as a certain unnamed government report suggests, might require a new manufacturing school.
The Department of Commerce released a memo that generic drug production is “robust” in theory but not robust enough in practice when the price of a single tablet climbs into the hundreds of dollars.
Critics point out that the U.S. already has a robust network of specialty drug firms that can produce high‑end pharmaceuticals. The challenge is turning that strength into a mass‑production model that competes with the low‑cost output of overseas manufacturers.
Some say the solution is to import the expertise, not the drugs: a “robust” partnership with Indian firms that would keep the money in the U.S. while letting the production happen where the labor is cheaper.
The final chapter of this saga might involve a bipartisan committee drafting a bill that guarantees a “robust” supply of generics while simultaneously funding a training program for American chemists. Until then, the dream of a fully domestic generic drug industry will remain a robust but unfulfilled fantasy.
Trump Flirts with Kim, Casts Spy Shadows on Alice Huang While Praising Jensen’s ‘Lesson’
President Trump hints at a rendezvous with North Korea’s leader, questions the allegiance of Alice Huang, and lauds Jensen Huang’s newly…